The culture of temporary tumor-like bone marrow mesenchymal stem cells (TT-BMSC) and the detection of cell biology property

Annals of Transplantation

Volumn 16, Issue 3, 2011, Pages 49-58

  Chen, Yi ^a   Cong, Lin ^a   Yin, Ximeng ^a   Dong, Baotie ^a   Han, Yaxin ^a   Tu, Guanjun ^a  

^a CHINA MEDICAL UNIVERSITY   (China)

Author keywords

Bone marrow mesenchymal stem cells; Matrix metalloproteinase 2; Phosphatase and tensin homolog deleted on chromosome ten; Ribonucleic acid interference

Indexed keywords

GELATINASE A; MATRIGEL; MESSENGER RNA; METHYLTHIAZOLYLTETRAZOLIUM; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; SMALL INTERFERING RNA; TETRAZOLIUM; UNCLASSIFIED DRUG;

ANOXIA; ARTICLE; CELL CULTURE; CELL CYCLE; CELL GROWTH; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; CELL SURVIVAL; CYTOLOGY; GENE EXPRESSION; ISCHEMIA; MESENCHYMAL STEM CELL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA INTERFERENCE; TEMPORARY TUMOR LIKE BONE MARROW MESENCHYMAL STEM CELL; WESTERN BLOTTING;

EID: 80054860457     PISSN: 14259524     EISSN: None     Source Type: Journal    
DOI: 10.12659/AOT.881995     Document Type: Article

References (24)

1. Abdallah BM, Kassem M: Human mesenchymal stem cells: from basic biology to clinical applications. Gene Ther, 2008; 15(2): 109-16
2. Trzaska KA, Kuzhikandathil EV, Rameshwar P: Specification of a dopaminergic phenotype from adult human mesenchymal stem cells. Stem Cells, 2007; 25: 2797-808
3. Tio M, Tan KH, Lee W et al: Roles of db-cAMP, IBMX and RA in aspects of neural differentiation of cord blood derived mesenchymal-like stem cells. PLoS One, 2010; 5(2): e9398
4. DJ: "Stemness" does not explain the repair of many tissues by mesenchymal stem/multipotent stromal cells (MSCs). Clin Pharmacol Ther, 2007; 82: 241-43
5. Vaquero J, Zurita M: Bone marrow stromal cells for spinal cord repair: a challenge for contemporary neurobiology. Histol Histopathol, 2009; 24: 107-16
6. Hawryluk GW, Rowland J, Kwon BK et al: Protection and repair of the injured spinal cord: Areview of completed, ongoing, and planned clinical trials for acute spinal cord injury. Neurosurg Focus, 2008; 25: e14
7. Owland JW, Hawryluk GW, Kwon B et al: Current status of acute spinal cord injury pathophysiology and emerging therapies: Promise on the horizon. Neurosurg Focus, 2008; 25: E2
8. Pittenger MF, Mackay AM, Beck SC et al: Multilineage potential of adult human mesenchymal stem cells. Science, 1999; 284: 143-47
9. Kentaro O, Kenichi Y, Shunsuke O et al: Nonviral delivery of siRNA into mesenchymal stem cells by a combination of ultrasound and microbubbles. J. Controlled Release, 2009; 133: 146-53
10. Rossi SL, Keirstead HS: Stem cells and spinal cord regeneration. Curr Opin Biotechnol, 2009; 20(5): 552-62
11. Salazar DL, Uchida N, Hamers FP et al: Human neural stem cells differentiate and promote locomotor recovery in an early chronic spinal cord injury NOD-scid mouse model. PLoS One, 2010; 5(8): e12272
12. Hill CE, Guller Y, Raffa SJ et al: A calpain inhibitor enhances the survival of schwann cells in vitro and after transplantation into the injured spinal cord. J Neurotrauma, 2010; 27(9): 1685-95
13. Wernig A, Wernig S, de Carvalho M, Lopes A: Olfactory ensheathing cells for human spinal cord injury. Neurorehabil Neural Repair, 2010; 24(8): 772-73
14. Cho JS, Park HW, Park SK et al: Transplantation of mesenchymal stem cells enhances axonal outgrowth and cell survival in an organotypic spinal cord slice culture. Neurosci Lett, 2009; 454(1): 43-48
15. Basak GW, Urbanowska E, Boguradzki P et al: Booster of plerixafor can be successfully used in addition to chemotherapy-based regimen to rescue stem cell mobilization failure. Ann Transplant, 2010; 15(4): 61-67
16. Matsunaga Y, Koda M, Murawaki Y: Expression of matrix metalloproiteinases (MMPs)and tissue inhibitors of metalloproteinases (TIMPs) in hepatocellular carcinoma tissue, compared with the surrounding non-tumor tissue. Res Commun Mol Pathol Pharmacol, 2004; 115: 143-50
17. Soreide K, Janssen EA, Korner H et al: Trypsin in colorectal cancer: molecular biological mechanisms of proliferation, invasion, and metastasis. J Pathol, 2006; 209: 147-56
18. Keniry M, Parsons R: The role of PTEN signaling perturbations in cancer and in targeted therapy. Oncogene, 2008; 27: 5477-85
19. Freeman DJ, Li AG, Wei G et al: PTEN tumor suppressor regulates p53 protein levels and activity through phosphatase-dependent and -independent mechanisms. Cancer Cell, 2003; 3: 117-30
20. Lei Q, Jiao J, Xin L et al: NKX3.1 stabilizes p53, inhibits AKT activation, and blocks prostate cancer initiation caused by PTEN loss. Cancer Cell, 2006; 9: 367-78
21. Shen WH, Balajee AS, Wang J et al: Essential role for nuclear PTEN in maintaining chromosomal integrity. Cell, 2007; 128: 157-70
22. Chen Z, Trotman LC, Shaffer D et al: Crucial role of p53-dependent cellular senescence in suppression of Pten-deficient tumorigenesis. Nature, 205; 436: 725-30
23. Reginald H, Hong W: PTEN, Stem Cells, and Cancer Stem Cells. J Biological Chemistry, 2009; 284: 11755-59
24. Knobbe CB, Lapin V, Suzuki A et al: The roles of PTEN in development, physiology and tumorigenesis in mouse models: a tissue-by-tissue survey. Oncogene, 2008; 27: 5398-415